HAELO: NTLA-2002 in Hereditary Angioedema

Market
100%75%50%25%0%Apr 26 • YES 58.0%Apr 26Apr 26 • YES 64.8%Apr 26
Trade

Will this trial meet its primary endpoint?

Paper Trading
Create account to trade
DetailsModel PositionsModel SnapshotsOracle
Primary Completion
4/1/26
Study Completion
9/1/27
Sponsor
Intellia Therapeutics
Ticker
$NTLA
Type
Phase 3
Trial Status
Active, not recruiting
Trial Size
60
NCT
NCT06634420
Trial Description
Phase 3 multinational, randomized, double-blind, placebo-controlled study evaluating a single IV infusion of NTLA-2002 versus placebo in approximately 60 participants with hereditary angioedema. The primary assessment is the time-normalized number of investigator-confirmed HAE attacks from Week 5 through Week 28, with longer-term follow-up after the primary observation period.